Borderline resectable pancreatic cancer (BRPC) is an intermediate stage between resectable and unresectable pancreatic cancer, characterized by having a chance to achieve radical resection technically but with high risk of positive surgical margin. In this paper, the authors address the recent advances in aspects of prognotic evaluation and treatment of this condition.